A case of HER2 positive advanced breast cancer treated by sequential therapy of initimumab,teripril monoclonal antibody and albumin paclitaxel
Objective To evaluate the safety and efficacy of sequential treatment with inetolimab,toripalimab combined with albumin paclitaxel in patients with HER-2 positive advanced breast cancer.Methods A case of HER2-positive stage ⅢA breast cancer was reported.The patient did not take anti-HER2 adjuvant treatment due to financial reasons after surgery.After the occurrence of multiple metastases,the patient entered the clinical trial,and received 8 cycles treatment of inetetamab,toripalimab and albumin paclitaxel.The sequential combination of inetetamab and toripalimab was sustained for 12 cycles.Results After 4 cycles of treatment,the patien was evaluated as complete response.The current progression-free survival has exceeded 16 months.The safety profile was good.Conclusion For HER2 positive advanced breast cancer,the combination of inetetamab,toripalimab and chemotherapy holds promise as a new first-line treatment option.
InetetamabToripalimabAlbumin paclitaxelAnti-HER2 therapyHER2-positive breast cancer
万方数据
维普
